Abstract: The present invention provides a system and method for measuring intermittent operating life (IOL) of a GaN-based device under test (DUT) is provided. The system is operable in a stressing mode, a cooling mode and a measure mode. A power regulation approach is adopted to ensure that DUT of the same thermal resistance have same temperature increase during the IOL test. The present invention eliminates the influence caused by parasitic parameters of testing circuits and the inconsistency of threshold voltage and drain-source resistance of the device itself. Through power regulation, it is the junction temperature of the device, not the housing temperature of the device, being directly controlled. Therefore, higher measurement accuracy can be achieved.

Abstract: A reluctance motor has salient teeth on both the stator and the rotor. The reluctance motor includes electrical coils that are usable to generate magnetic flux to drive rotation of the rotor. Concentrated coil windings are wound around each stator tooth. The electrical coils are arranged across all the stator teeth of the reluctance motor to enable the reluctance motor to be driven by alternating current. The electrical coils are arranged so that, when excited with alternating current, the number of magnetic half-poles is equal to the number of teeth on the rotor. The reluctance machine can operate using an inverter instead of an asymmetric bridge.

Abstract: The subject application provides an apparatus and method for measuring dynamic on-resistance of a device under test (DUT) comprising a control terminal electrically connected to an output of a first controlling module being configured to generate a first control signal to switch on and off the DUT. The apparatus comprises a switching device and a second controlling module configured to: receive the first control signal from the first controlling module and generate a second control signal to switch on and off the switching device such that the switching device is turned on later than the DUT for a first time interval and turned off earlier than the DUT for a second time interval.

Abstract: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.

Abstract: Methods for reducing anxiety such as worrying or bothering about the ocular disease and/or eye appearance in pterygia patients are described. The methods can include administration of a multikinase inhibitor, for example nintedanib, to patients in need thereof.

Abstract: Provided are amphiphilic copolymers that include repeat units of formulas [Z]m and [P]n, wherein Z is a zwitterionic structural unit including at least one pendant heteroaromatic moiety, the heteroaromatic moiety containing a positively charged quaternary nitrogen atom (e.g., a pyridine ring), and wherein at least one negatively charged functional moiety is linked to the heteroaromatic moiety directly or through a linker, wherein the linker, where present, is an optionally substituted alkyl linker; P is a structural unit including a hydrophobic moiety, the hydrophobic moiety being a linear, branched, or cyclic fluorine-substituted C1-C20 moiety; m is an integer that is ?1; and n is an integer that is ?1.

Abstract: Various embodiments of the present technology generally relate to multi-frequency satellite navigation receiver technology. More specifically, some embodiments relate to an inter-frequency signal aiding technique for multi-frequency signal tracking in a multi-frequency receiver. The present technology enables a satellite navigation receiver (such as GPS) to continue operation, or to have improved performance, in environments where signals on one or more frequency bands experience fading. Some embodiments can estimate parameters of signal channels that experience fading based on measurements obtained from all or other less compromised frequency bands in linear operation by the receiver. Some embodiments can optimally estimate carrier parameters of navigation signals with consideration of relative measurement qualities. These parameters are used to construct the local reference signals, maintain lock on the fading signals, and obtain accurate positioning solutions and remote sensing observations.

Abstract: An embodiment provides a system for measuring temperature and deformation fields of at least a portion of a sample, comprising a visible light camera, an infrared camera, and a beam splitter. The visible light camera is at a first location with respect to the sample and can take a visible light image of at least a portion of the sample at a first time. The infrared camera is at a second location with respect to the sample and can take an infrared image of the at least a portion of the sample at the first time. The beam splitter can receive a beam of light, comprising infrared and visible light, traveling in a direction normal to the at least a portion of the sample and direct the infrared light to the infrared camera and the visible light to the visible light camera.

Abstract: Provided is a magnetic refrigeration device, including a first assembly and a second assembly, herein the second assembly is an annular assembly, the first assembly is located on a radial outer side or a radial inner side of the second assembly, the first assembly is a first magnet assembly, the second assembly is provided with an air gap space capable of accommodating a magnetic working medium bed, the first assembly is configured to rotate relative to the second assembly, and directions of a magnetic line of force of the first magnet assembly are distributed in the circumferential direction of the annular second assembly.

Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

Abstract: The disclosure provides a method and an apparatus for controlling ZigBee® sensors. The method comprises: selecting a second coordinator of a second ZigBee® network as a backup coordinator; detecting whether there is a failure of a first ZigBee® coordinator; and if a failure of the working coordinator is detected, designating the second ZigBee® coordinator as the networking coordinator for the end user devices in the first ZigBee® network to join the second ZigBee® network.

Abstract: A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and a semifluorinated alkane, as a liquid vehicle. The topical ophthalmological composition treats an ocular disease.

Abstract: Electrical impulses are received from a beating heart. The electrical impulses are converted to an ECG waveform. The ECG waveform is converted to a frequency domain waveform, which, in turn, is separated into two or more different frequency domain waveforms, which, in turn, are converted into a plurality of time domain cardiac electrophysiological subwaveforms and discontinuity points between these subwaveforms. The plurality of subwaveforms and discontinuity points are compared to a database of subwaveforms and discontinuity points for normal and abnormal patients or to a set of rules developed from the database. A bundle branches (BB) to J-Point (BB-J) interval is identified from the plurality of subwaveforms and discontinuity points based on the comparison. The ECG waveform with the BB-J interval annotated is displayed.

Abstract: A composition for use in the treatment of rosacea includes a multi-kinase inhibitor that inhibits both a Vascular Endothelial Growth Factor Receptor and a Fibroblast Growth Factor Receptor. A method for treating rosacea for a patient includes inhibiting a Vascular Endothelial Growth Factor Receptor of the patient; and inhibiting a Fibroblast Growth Factor Receptor of the patient.

Abstract: This disclosure relates to pharmaceutical chemistry, and more particularly to a metalloporphyrin compound, and a preparation and application thereof. The metalloporphyrin compound is shown in formula (I), or an optical isomer, a pharmaceutically-acceptable salt or a solvate thereof, and can specifically recognize the HIV RNA and effectively inhibit HIV reverse transcriptase. This disclosure also provides uses of the compound in the preparation of a reagent for selectively recognizing HIV TAR RNA and a HIV reverse transcriptase inhibitor.

Abstract: A method for treating a meibomian gland dysfunction of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of a cyclic polysaccharide. A steroidal-androgen-free composition includes a cyclic polysaccharide as an active pharmaceutical ingredient for treating a meibomian gland dysfunction of an affected eye.